🇺🇸 FDA
Pipeline program

Pravafenix 40 mg/160 mg hard capsules

ROFE-III-24-1

Phase 3 small_molecule active

Quick answer

Pravafenix 40 mg/160 mg hard capsules for Dyslipidaemia is a Phase 3 program (small_molecule) at Laboratoire HRA Pharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Laboratoire HRA Pharma
Indication
Dyslipidaemia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials